Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06224413 · ClinicalTrials.gov registry record
A Study of Participants With Cerebral Adrenoleukodystrophy (CALD) Treated With Elivaldogene Autotemcel
A clinical trial of Cerebral Adrenoleukodystrophy (CALD), sponsored by Genetix Biotherapeutics.
- Recruiting
- Registry status
- 120
- Enrollment target
- 3
- Study locations
NCT06224413: Recruiting study of Cerebral Adrenoleukodystrophy (CALD), sponsored by Genetix Biotherapeutics.
NCT06224413 is a study of Cerebral Adrenoleukodystrophy (CALD) that is actively recruiting participants, run by Genetix Biotherapeutics. The registered enrollment target is 120 participants, above the 45-participant average among 3 other Cerebral Adrenoleukodystrophy (CALD) trials with a reported enrollment target (167% higher). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06224413, a study of Cerebral Adrenoleukodystrophy (CALD), is actively recruiting participants, sponsored by Genetix Biotherapeutics.
- RECRUITING
- Registry status
- 120 participants
- Enrollment target
- 3
- Study locations
Study Summary
The main aim of this study is to assess and describe the safety outcomes, including newly diagnosed malignancies, of patients with CALD treated with eli-cel in the post-marketing setting (tradename Skysona) and to describe major functional disability (MFD)-free survival over time in participants with more advanced early active CALD. All enrolled participants with CALD treated with eli-cel in the post-marketing setting will be followed in this study for 15 years. No investigational drug product will be administered in this study. This study will enroll 120 participants with CALD treated with eli-cel in the post-marketing setting. A subpopulation of 24 participants with more advanced early active CALD will be specifically enrolled as required by the US FDA as a condition of accelerated approval and will be considered as a separate cohort for effectiveness outcomes.
Primary Outcome
The Sponsor considers the following events to be AEIs (which should be reported as a medically significant Serious Adverse Events \[SAEs\]): * Any newly diagnosed malignancy * Neutrophil engraftment failure: defined as health care provider (HCP) decision to administer back-up cells or subsequent hematopoietic stem cell transplantation (HSCT) due to neutrophil recovery failure * Newly acquired HIV-1 or HIV-2 infection * Any newly diagnosed autoimmune disorders * Opportunistic infections * Grade
Conditions Studied
Interventions
- OTHER No Intervention
Study Locations (3)
Massachusetts
- Boston Children's Hospital - Boston
Pennsylvania
- Children's Hospital of Philadelphia - Philadelphia
Texas
- UT Southwestern Medical Center - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2024-03-27 |
| Est. Completion | 2047-12-30 |
What NCT06224413 shows while recruiting
NCT06224413 is an observational study that tracks outcomes without assigning an intervention. The registered 120 participants enrollment target is mid-sized for trials with a published cap, above the 45-participant average among 3 other Cerebral Adrenoleukodystrophy (CALD) trials with a reported enrollment target (167% higher).
The record links to 1 condition, with Cerebral Adrenoleukodystrophy (CALD) appearing as the primary indexed condition, and to 1 intervention - of which No Intervention is the first listed.
NCT06224413 reports a single indexed study location in Massachusetts, Pennsylvania, Texas.
Frequently Asked Questions
What is clinical trial NCT06224413 about?
NCT06224413 is a clinical study titled "A Study of Participants With Cerebral Adrenoleukodystrophy (CALD) Treated With Elivaldogene Autotemcel". The main aim of this study is to assess and describe the safety outcomes, including newly diagnosed malignancies, of patients with CALD treated with eli-cel in the post-marketing setting (tradename Skysona) and to describe major functional disability (MFD)-free survival over time in participants wit...
What is the current status of trial NCT06224413?
This trial is currently recruiting. The enrollment target is 120 participants. The study started on 2024-03-27. Estimated completion is 2047-12-30.
What conditions does trial NCT06224413 study?
This clinical trial studies the following conditions: Cerebral Adrenoleukodystrophy (CALD).
What interventions are being tested in trial NCT06224413?
The interventions under investigation include: No Intervention (OTHER).
Who is sponsoring clinical trial NCT06224413?
This trial is sponsored by Genetix Biotherapeutics, which has 12 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06224413 being conducted?
This trial has 3 study locations across Massachusetts, Pennsylvania, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cerebral Adrenoleukodystrophy (CALD)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Clinical Study to Assess the Efficacy and Safety of Leriglitazone in Adult Male Subjects With Cerebral Adrenoleukodystrophy
RECRUITING · Phase 3
-
Long-term Follow-up of Participants With Cerebral Adrenoleukodystrophy Who Were Treated With Lenti-D Drug Product
ACTIVE NOT RECRUITING
-
A Study of the Efficacy and Safety of Hematopoietic Stem Cells Transduced With Lenti-D Lentiviral Vector for the Treatment of Cerebral Adrenoleukodystrophy (CALD)
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01174108 · 120 participants · Phase 2
Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells
- NCT01627301 · 120 participants · NA
Sympathetic Overactivity in Post-traumatic Stress Disorder
- NCT02025023 · 120 participants · Phase 3
Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study
- NCT02128906 · 120 participants · Phase 2
Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI